Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear receptor subfamily 1, group I, member 2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | ecdysteroid receptor | nuclear receptor subfamily 1, group I, member 2 | 434 aa | 427 aa | 25.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0361 | 1 | 1 |
Schistosoma mansoni | dihydropteridine reductase | 0.0024 | 0.0351 | 1 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0024 | 0.0351 | 1 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0024 | 0.0351 | 0.5 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0024 | 0.0351 | 1 |
Trypanosoma brucei | pteridine reductase 1 | 0.0024 | 0.0351 | 0.5 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0024 | 0.0351 | 0.5 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0024 | 0.0351 | 1 |
Loa Loa (eye worm) | oxidoreductase | 0.0024 | 0.0351 | 1 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0024 | 0.0351 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0361 | 1 | 1 |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0024 | 0.0351 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0361 | 1 | 1 |
Leishmania major | oxidoreductase-like protein | 0.0024 | 0.0351 | 0.5 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0024 | 0.0351 | 0.5 |
Loa Loa (eye worm) | retinol dehydrogenase 12 | 0.0024 | 0.0351 | 1 |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0024 | 0.0351 | 0.5 |
Leishmania major | pteridine reductase 1 | 0.0024 | 0.0351 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0361 | 1 | 1 |
Onchocerca volvulus | 0.0024 | 0.0351 | 1 | |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0361 | 1 | 1 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0361 | 1 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0361 | 1 | 1 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0024 | 0.0351 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0361 | 1 | 0.5 |
Onchocerca volvulus | 0.0024 | 0.0351 | 1 | |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0024 | 0.0351 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.0351 | 1 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0024 | 0.0351 | 0.5 |
Echinococcus granulosus | 3 oxoacyl acyl carrier protein reductase | 0.0024 | 0.0351 | 1 |
Echinococcus multilocularis | 3 oxoacyl acyl carrier protein reductase | 0.0024 | 0.0351 | 1 |
Schistosoma mansoni | 3-oxoacyl-[ACP] reductase | 0.0024 | 0.0351 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | = 5.5 uM | Activation of PXR in human DPX2 cells after 24 hrs by luciferase reporter gene assay | ChEMBL. | 22452568 |
FC (binding) | = 5.9 | Activation of PXR in human DPX2 cells after 24 hrs by luciferase reporter gene assay relative to control | ChEMBL. | 22452568 |
MIC90 (functional) | = 0.07 uM | Antitubercular activity against Mycobacterium tuberculosis H37Rv in aerobic conditions after 7 days by microplate-based alamar blue assay | ChEMBL. | 22452568 |
MIC90 (functional) | = 0.4 uM | Antitubercular activity against Mycobacterium tuberculosis H37Rv in anaerobic conditions after 11 days by luminescnece-based low-oxygen recovery assay | ChEMBL. | 22452568 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.